rudolf koehne-volland head of biostatistics & ceo...
TRANSCRIPT
Best practice in dose finding studies
Rudolf Koehne-Volland
Head of Biostatistics & CEO
Metronomia Clinical Research GmbH
Best practice in dose finding studies
Agenda
What is the problem?
Dose finding requirements
Dose finding approaches
Challenges
Conclusion
13-Oct-2016 3 Best practices in dose finding studies || CTEF Munich 2016
Success rates in drug development Trends over time
13-Oct-2016 Best practices in dose finding studies || CTEF Munich 2016 4
Source: CMR International 2015 Global R&D Performance Metrics Programme
Attrition reasons 2013 & 2014
13-Oct-2016 Best practices in dose finding studies || CTEF Munich 2016 5
In many cases homework was not done in Phase II
Not learning as much as necessary about a new treatment
Not generating a good data basis or know-how for planning Phase III
Reason Phase II Phase III & Reg review
Efficacy 49% 53%
Safety 31% 25%
Strategy 19% 5%
Source: Cortellis Competitive Intelligence & Thomson Reuters Integrity
2000 − 2012 around 16% of FDA NME filings failed to be approved first time due to “uncertainties related to dose selection” (Sacks et al., 2014)
21% of drugs filed in 1980 − 1999 had post-approval dosage changes or were removed from sale (Cross et al., 2002)
Poor dose finding and failure
13-Oct-2016 6 Best practices in dose finding studies || CTEF Munich 2016
Source: Cortellis Competitive Intelligence & Thomson Reuters Integrity
Characterizing dose response for safety and efficacy is critical
dose too high safety and tolerability problems are likely to result
dose too low may lead to inadequate efficacy
Therapeutic window: doses that are both efficacious and safe
Optimal dose: a trade-off between efficacy and safety
What is the problem?
Dose finding challenge
13-Oct-2016 7 Best practices in dose finding studies || CTEF Munich 2016
clinically relevant effect
efficacy
dose d1
Response
safety threshold
safety
dose d2
Pr(
dose t
ole
rate
d)
1
Agenda
What is the problem?
Dose finding requirements
Dose finding approaches
Challenges
Conclusion
13-Oct-2016 8 Best practices in dose finding studies || CTEF Munich 2016
Paracelsus (1493 – 1541)
13-Oct-2016 9 Best practices in dose finding studies || CTEF Munich 2016
“All things are poison and
nothing is without poison,
only the dose permits something not to be poison.”
ICH E4 Dose Response Information to Support Drug Registration
13-Oct-2016 10 Best practices in dose finding studies || CTEF Munich 2016
Selecting the right dose
Paracelsus: ~ 500 years ago
ICH E4: >20 years ago
2000 − 2012: ~ 16% of FDA NME filings failed due to “uncertainties related to dose selection”
Are we doing ok?
We are probably not doing ok!
13-Oct-2016 11 Best practices in dose finding studies || CTEF Munich 2016
13-Oct-2016 12 Best practices in dose finding studies || CTEF Munich 2016
Source: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/04/WC500185864.pdf
EMA Report from Dose Finding Workshop 2014
13-Oct-2016 13 Best practices in dose finding studies || CTEF Munich 2016
Source: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/04/WC500185864.pdf
EMA Report from Dose Finding Workshop 2014
13-Oct-2016 14 Best practices in dose finding studies || CTEF Munich 2016
Source: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/04/WC500185864.pdf
EMA Report from Dose Finding Workshop 2014
13-Oct-2016 15 Best practices in dose finding studies || CTEF Munich 2016
Source: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/04/WC500185864.pdf
Times are changing
Better dose finding is required by …
Regulatory guidance
Medical & scientific needs
Drug development business
Biotech business model
potential pharma investors look more carefully into dose finding
… and even request certain study designs and methods
13-Oct-2016 16 Best practices in dose finding studies || CTEF Munich 2016
Agenda
What is the problem?
Dose finding requirements
Dose finding approaches
Challenges
Conclusion
13-Oct-2016 17 Best practices in dose finding studies || CTEF Munich 2016
Dose finding approaches in Phase I
Most common objective
Identification of the maximum tolerated dose (MTD)
Most frequently used study design
3+3 design (and its modifications) are used since decades
Alternatives
Accelerated titration design
Adaptive dose finding designs incl. Bayesian model based methods (e.g. continual reassessment method)
13-Oct-2016 18 Best practices in dose finding studies || CTEF Munich 2016
13-Oct-2016 19 Best practices in dose finding studies || CTEF Munich 2016
Source: http://meetinglibrary.asco.org/sites/meetinglibrary.asco.org/files/edbook/156/pdf/EdBookAM2015353.pdf
Agenda
What is the problem?
Dose finding requirements
Dose finding approaches
In Phase I
In Phase II
Challenges
Conclusion
13-Oct-2016 20 Best practices in dose finding studies || CTEF Munich 2016
Multiple, parallel dose groups
Placebo controlled, sometimes also with active controll
Randomized
Phase II dose finding studies
Standard study design
13-Oct-2016 Best practices in dose finding studies || CTEF Munich 2016 21
Establish evidence of a dose-response relationship (proof of concept)
Is there a dose related effect at all?
What is the maximum effect size?
What is the nature of the dose response shape?
Go / no go decision to Phase III
If “go”: Selection of optimal dose for Phase III
Phase II dose finding studies
Objectives
13-Oct-2016 Best practices in dose finding studies || CTEF Munich 2016 22
Pairwise comparisons
Pairwise comparisons of active doses against placebo (e.g. ANOVA-based hypothesis testing or hierarchical testing)
Drawback: Available information across all active doses is not considered efficiently
Questions
What happens in-between the doses?
What is the dose-response curve?
Do you want to rely on point estimates?
Phase II dose finding studies
Most frequently used statistical method
13-Oct-2016 Best practices in dose finding studies || CTEF Munich 2016 23
Dose
*
*
* Statistically significant better than placebo, but no difference between the two
Phase II dose finding studies
EMA Report from Dose Finding Workshop 2014
Source: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/04/WC500185864.pdf
13-Oct-2016 Best practices in dose finding studies || CTEF Munich 2016 24
Statistical testing is normally done in Phase III and requires large sample sizes Testing in Phase II with much lower sample sizes is often not
adequately powered
Pairwise comparisons in dose finding trials are open to by chance findings – particularly if not adequately powered
Often only a small number of doses is studied
Phase II dose finding studies
Issues with pairwise comparisons
13-Oct-2016 Best practices in dose finding studies || CTEF Munich 2016 25
Model based analysis!
Modeling provides more information
Smoothens dose estimates
Interpolation between doses
Confidence intervals for quantities of interest
Phase II dose finding studies
How to improve?
Dose
Sta
nd
ard
ize
d d
iffe
ren
ce
to
pla
ce
bo
13-Oct-2016 Best practices in dose finding studies || CTEF Munich 2016 26
True shape of dose response model is typically unknown
Selecting a working model may have a substantial impact on the final dose estimate
Model selection using observed data needs to account for the inherent uncertainty
Useful to have a unified approach combining the advantages of dose response signal testing and modeling
MCP-Mod: Combination of
Multiple Comparison Procedures and Modelling
Phase II dose finding studies
How to improve?
13-Oct-2016 27 Best practices in dose finding studies || CTEF Munich 2016
Dose
Sta
nd
ard
ize
d d
iffe
ren
ce
to
pla
ce
bo
Phase II dose finding studies
MCP-Mod approach
13-Oct-2016 28 Best practices in dose finding studies || CTEF Munich 2016
Source: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2014/02/WC500161027.pdf
MCP step
Testing dose response signal based on a set of candidate models
Out of the significant models, the model with the best fit is selected
Mod step
The dose response curve is estimated using the selected model (or by model averaging of significant models)
Relevant parameters like ED50 (dose that achieves 50% of the maximum achievable effect) or the Minimal effective dose (MED) can be derived
Phase II dose finding studies
MCP-Mod approach
13-Oct-2016 29 Best practices in dose finding studies || CTEF Munich 2016
Phase II dose finding studies
MCP-Mod approach
13-Oct-2016 30 Best practices in dose finding studies || CTEF Munich 2016
Source: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2014/02/WC500161027.pdf
Moderate sample sizes allow well powered MCP-Mod studies for proof of concept, i.e. for establishing a dose response relationship
A meaningfull precision for dose estimates (e.g. the MED) can only be achieved with higher sample sizes
There is nothing like a free lunch
MCP-Mod is clearly preferable to pairwise comparisons
However, the full potential is associated with higher sample sizes
MCP-Mod
Points to consider
13-Oct-2016 35 Best practices in dose finding studies || CTEF Munich 2016
Planning is important and requires a joint effort of clinicians, pharmacologists and statisticians
What are candidate dose response curves?
What is the dose range, e.g. the maximum dose to be included?
Which doses and number of doses shall be studied?
What is the minimal clinically important effect?
What precision is expected, e.g. for the MED?
Involves simulation studies
Takes more time
MCP-Mod
Points to consider
13-Oct-2016 36 Best practices in dose finding studies || CTEF Munich 2016
Agenda
What is the problem?
Dose finding requirements
Dose finding approaches
Challenges
Conclusion
13-Oct-2016 37 Best practices in dose finding studies || CTEF Munich 2016
Implementing proper dose finding studies
Challenges
Time and financial pressure
Lack of experience with methods
Implementation and statistical analysis
13-Oct-2016 38 Best practices in dose finding studies || CTEF Munich 2016
Implementing proper dose finding studies
Challenges
Create awareness of importance of scientifically sound and meaningful dose finding studies
Overcome adherence to what has been done in the past
Regulatory guidances
Examples
13-Oct-2016 39 Best practices in dose finding studies || CTEF Munich 2016
Implementing proper dose finding studies
Challenges
Convince your team that its worth the additional effort
Much better decision making
Better regulatory acceptance
Better treatments
„If you buy cheaply (in Phase II), you pay dearly (in Phase III)!”
13-Oct-2016 40 Best practices in dose finding studies || CTEF Munich 2016
Agenda
What is the problem?
Dose finding requirements
Dose finding approaches
Challenges
Conclusion
13-Oct-2016 41 Best practices in dose finding studies || CTEF Munich 2016
Conclusions
Phase II dose finding studies should be designed and analysed in order to get a good understanding of the dose response relationship
More dose levels and cover the entire dose range
Use modelling techniques (e.g. MCP-Mod) rather than pairwise comparions
Proper dose finding studies allow much better decision making
We could do better in drug research, we just have to start doing it
Better methods are available and strongly supported by regulatory bodies
Better research in phase II will pay off
13-Oct-2016 42 Best practices in dose finding studies || CTEF Munich 2016
Thank you very much!
Rudolf Koehne-Volland
+49 89 829265 222
13-Oct-2016 43 Best practices in dose finding studies || CTEF Munich 2016